<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2402">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05129891</url>
  </required_header>
  <id_info>
    <org_study_id>NN9501-4821</org_study_id>
    <secondary_id>U1111-1266-0672</secondary_id>
    <secondary_id>2021-001452-34</secondary_id>
    <nct_id>NCT05129891</nct_id>
  </id_info>
  <brief_title>A Research Study Looking at New Protein-based Tablets in Healthy Male Participants</brief_title>
  <official_title>A Study Investigating Pharmacokinetic Properties When Dosing Different Formulations of Oral Peptide Therapeutics in Healthy Male Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, four new tablet versions of two compounds will be investigated.&#xD;
&#xD;
      The aim of this study is to investigate the amount of the active ingredient and helping agent&#xD;
      in the blood after doses of four different tablet versions. The tablet versions, participants&#xD;
      will receive, i.e. the treatment arm participants will be assigned to, is decided by chance.&#xD;
&#xD;
      Participants will receive one treatment for 10 days in the first period. For the second&#xD;
      period, directly following, participants will receive a different treatment for five more&#xD;
      days.&#xD;
&#xD;
      The study can last for up to approximately 10 weeks for each participant. This includes a&#xD;
      screening period (up to 3 weeks), two treatment periods (together a total of 15 days) and a&#xD;
      follow-up visit (5 weeks after the last dosing)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2021</start_date>
  <completion_date type="Anticipated">November 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-24h,API,day10; area under the API plasma concentration-time curve from 0 to 24 hours after the 10th dose</measure>
    <time_frame>From pre-dose PK sample (0 hours) at day 10 to PK sample 24 hours after dose administration</time_frame>
    <description>h * nmol/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax,API,day10; maximum observed plasma concentration of API after the 10th dose</measure>
    <time_frame>From pre-dose PK sample (0 hours) at day 10 to PK sample 24 hours after dose administration</time_frame>
    <description>nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax, API,day10; time from the 10th dose to maximal observed plasma concentration of API</measure>
    <time_frame>From pre-dose PK sample (0 hours) at day 10 to PK sample 24 hours after dose administration</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">384</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>High Blood Cholesterol Levels</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Part A: Oral semaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four different formulations of oral semaglutide are investigated. One formulation given for 10 days before participants receive a different formulation for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: NNC0385-0434</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four different formulations of NNC0385-0434 are investigated. One formulation given for 10 days before participants receive a different formulation for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide D</intervention_name>
    <description>Tablet given orally</description>
    <arm_group_label>Part A: Oral semaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide G</intervention_name>
    <description>Tablet given orally</description>
    <arm_group_label>Part A: Oral semaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide H</intervention_name>
    <description>Tablet given orally</description>
    <arm_group_label>Part A: Oral semaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide I</intervention_name>
    <description>Tablet given orally</description>
    <arm_group_label>Part A: Oral semaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0385-0434 B</intervention_name>
    <description>Tablet given orally</description>
    <arm_group_label>Part B: NNC0385-0434</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0385-0434 C</intervention_name>
    <description>Tablet given orally</description>
    <arm_group_label>Part B: NNC0385-0434</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0385-0434 D</intervention_name>
    <description>Tablet given orally</description>
    <arm_group_label>Part B: NNC0385-0434</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0385-0434 E</intervention_name>
    <description>Tablet given orally</description>
    <arm_group_label>Part B: NNC0385-0434</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male.&#xD;
&#xD;
          -  Aged 18-55 years (both inclusive) at the time of signing informed consent.&#xD;
&#xD;
          -  Body mass index between 20.0 and 29.9 kg/m^2 (both inclusive).&#xD;
&#xD;
          -  Considered to be generally healthy based on the medical history, physical examination,&#xD;
             and the results of vital signs, electrocardiogram and clinical laboratory tests&#xD;
             performed during the screening visit, as judged by the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected hypersensitivity to study interventions or related products.&#xD;
&#xD;
          -  Use of prescription medicinal products or non-prescription drugs (including herbal&#xD;
             products and vaccines), except routine vitamins and topical medications not reaching&#xD;
             the systemic circulation, within 14 days prior to the day of screening.&#xD;
&#xD;
          -  Any disorder which in the investigator's opinion might jeopardise participant safety&#xD;
             or compliance with the protocol.&#xD;
&#xD;
          -  Presence of clinically significant gastrointestinal disorders potentially affecting&#xD;
             absorption of drugs and/or nutrients, as judged by the investigator.&#xD;
&#xD;
          -  History (as declared by the participant or reported in the medical records) of major&#xD;
             surgical procedures involving the stomach potentially affecting absorption of study&#xD;
             products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass&#xD;
             surgery).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Transparency (dept. 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

